Tekla Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Tekla Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-36,351	Closed	-$1.82M	–	151
2016 Q3	$1.82M	Hold	36,351	–	–	0.07%	121
2016 Q2	$1.54M	Sell	36,351 -36,083	-50%	-$1.97M	0.06%	139
2016 Q1	$4.77M	Sell	72,434 -36,082	-33%	-$1.88M	0.2%	86
2015 Q4	$6.75M	Hold	108,516	–	–	0.24%	77
2015 Q3	$7.27M	Buy	108,516 +36,350	+50%	+$2.97M	0.26%	84
2015 Q2	$7.02M	Hold	72,166	–	–	0.25%	73
2015 Q1	$6.75M	Hold	72,166	–	–	0.27%	72
2014 Q4	$6.42M	Hold	72,166	–	–	0.3%	65
2014 Q3	$4.99M	Hold	72,166	–	–	0.23%	78
2014 Q2	$4.14M	Sell	72,166 -24,055	-25%	-$1.22M	0.38%	49
2014 Q1	$3.82M	Hold	96,221	–	–	0.38%	48
2013 Q4	$4.04M	Sell	96,221 -32,074	-25%	-$930K	0.42%	39
2013 Q3	$3.84M	Buy	128,295 +59,966	+88%	+$2.1M	0.43%	48
2013 Q2	$3.62M	Buy	+68,329	New	+$3M	0.49%	46

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Tekla Capital Management's MACK Position: Q4 2016 in Review

Tekla Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2016, closing a stake of 36,351 shares — an estimated $1.82M sold.

Tekla Capital Management first reported a position in MACK in Q2 2013 and held it in 14 quarters. The position peaked at $7.27M in Q3 2015. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

Tekla Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Tekla Capital Management sold 36,351 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $1.82M.
Tekla Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 14 quarters.
Tekla Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $7.27M in Q3 2015.
136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on Tekla Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.